M Puoti

Summary

Country: Italy

Publications

  1. ncbi Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Spedali Civili, P le Ospedale Civili 1, I 25123 Brescia, Italy
    J Infect Dis 181:2033-6. 2000
  2. ncbi Mortality for liver disease in patients with HIV infection: a cohort study
    M Puoti
    II Divisione di Malattie Infettive, Azienda Spedali Civili, Brescia, Italy
    J Acquir Immune Defic Syndr 24:211-7. 2000
  3. ncbi Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Spedali Civili, Piazza Ospedale 1, I 25123 Brescia, Italy
    J Infect Dis 183:134-7. 2001
  4. ncbi Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone
    M Puoti
    Clinic for Infectious and Tropical Diseases, Brescia Hospital, Italy
    Dig Liver Dis 33:163-72. 2001
  5. ncbi Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome
    Massimo Puoti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, Italy
    J Acquir Immune Defic Syndr 32:259-67. 2003
  6. ncbi HIV/HCV co-infection: natural history
    M Puoti
    Department of Infectious and Tropical Diseases, University of Brescia and AO Spedali Civili, Brescia, Italy
    J Biol Regul Homeost Agents 17:144-6. 2003
  7. ncbi Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
    M G Antonini
    Dept of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Infection 36:250-5. 2008
  8. ncbi [Treatment of HCV infection in HIV-positive patients]
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Universita, e Azienda Ospedaliera Spedali Civili, Brescia
    Recenti Prog Med 92:618-23. 2001
  9. ncbi Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis
    D Manno
    Dept of Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy
    Infection 37:334-9. 2009
  10. ncbi Alcohol and coffee drinking and smoking habit among subjects with HCV infection
    C Zani
    Department of Experimental and Applied Medicine, Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy
    Dig Liver Dis 41:599-604. 2009

Detail Information

Publications54

  1. ncbi Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Spedali Civili, P le Ospedale Civili 1, I 25123 Brescia, Italy
    J Infect Dis 181:2033-6. 2000
    ..The relationship between HCV RNA increase and HIV RNA decrease indicates virus-virus interference. An HCV RNA increase may cause significant liver damage only in a minority of patients...
  2. ncbi Mortality for liver disease in patients with HIV infection: a cohort study
    M Puoti
    II Divisione di Malattie Infettive, Azienda Spedali Civili, Brescia, Italy
    J Acquir Immune Defic Syndr 24:211-7. 2000
    ..8-21.7) and history of alcohol abuse (OR, 2.3; 95% CI, 1-5.2). Prevention and treatment of hepatitis B virus infection and alcohol intake are management priorities in HIV-seropositive patients...
  3. ncbi Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Spedali Civili, Piazza Ospedale 1, I 25123 Brescia, Italy
    J Infect Dis 183:134-7. 2001
    ..2; P=.037), independent of HIV infection and other factors. These results suggest that HIV infection-induced CD4 depletion is independently associated with the severity of liver fibrosis in chronic HCV infection...
  4. ncbi Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone
    M Puoti
    Clinic for Infectious and Tropical Diseases, Brescia Hospital, Italy
    Dig Liver Dis 33:163-72. 2001
    ..Recent kinetic studies revealed that these doses may be suboptimal...
  5. ncbi Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome
    Massimo Puoti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, Italy
    J Acquir Immune Defic Syndr 32:259-67. 2003
    ..To assess incidence, risk factors, histology, and outcome of severe hepatotoxicity (SH) during antiretroviral treatment (ART)...
  6. ncbi HIV/HCV co-infection: natural history
    M Puoti
    Department of Infectious and Tropical Diseases, University of Brescia and AO Spedali Civili, Brescia, Italy
    J Biol Regul Homeost Agents 17:144-6. 2003
    ..However two recent studies showed that HCV coinfection is independently associated with a lower restoration of CD4 counts during combination antiretroviral treatment. However this finding should be confirmed by additional studies...
  7. ncbi Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
    M G Antonini
    Dept of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Infection 36:250-5. 2008
    ..Combination therapy with pegylated interferon (peginterferon) plus ribavirin is associated with several side effects, including neutropenia and infection...
  8. ncbi [Treatment of HCV infection in HIV-positive patients]
    M Puoti
    Clinica di Malattie Infettive e Tropicali, Universita, e Azienda Ospedaliera Spedali Civili, Brescia
    Recenti Prog Med 92:618-23. 2001
    ..Then the cost-effectiveness of anti HCV therapy in anti HIV infected patients still needs to be defined...
  9. ncbi Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis
    D Manno
    Dept of Infectious and Tropical Diseases, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy
    Infection 37:334-9. 2009
    ..A study was performed to describe the clinical features and factors predictive of mortality and prolonged hospitalization in cirrhotic HIV-infected patients with a diagnosis of CABP...
  10. ncbi Alcohol and coffee drinking and smoking habit among subjects with HCV infection
    C Zani
    Department of Experimental and Applied Medicine, Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy
    Dig Liver Dis 41:599-604. 2009
    ....
  11. ncbi Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy
    G Rossi
    Sezione Ematologia, Universita di Brescia, Spedali Civili, Brescia, Italy
    Br J Haematol 115:58-62. 2001
    ..Thus, primary prophylaxis with lamivudine may be a well tolerated and effective method to reduce the frequency of chemotherapy-induced HBV reactivation in chronic HBsAg carriers...
  12. ncbi HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
    Antonella D arminio Monforte
    Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
    AIDS 22:2143-53. 2008
    ..To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency...
  13. ncbi Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    J Hepatol 44:S146-50. 2006
    ..Prevention of hepatitis and cirrhosis are key goals in reducing the impact of HCC. Numerous issues in HCC prevention, diagnosis, and management still remain to be resolved through large-scale, randomized clinical trials...
  14. ncbi Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007
  15. ncbi Natural history of chronic hepatitis B in co-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
    J Hepatol 44:S65-70. 2006
    ....
  16. ncbi Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Francesca Gatti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Rev 9:16-24. 2007
    ....
  17. ncbi Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Paola Cicconi
    Clinic of Infectious Diseases and Tropical Medicine University of Milan, Milan, Italy
    AIDS 21:599-606. 2007
    ..To investigate if the risk of liver enzyme elevation (LEE) in HIV/hepatitis B or C (HBV, HCV) co-infection is altered by HAART (two or more drugs)...
  18. ncbi Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis
    Massimo Puoti
    Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia, Brescia, Italy
    Antivir Ther 11:567-74. 2006
    ..The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied...
  19. ncbi Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy
    Giuseppe Lapadula
    Istituto per le Malattie Infettive e Tropicali, , Brescia, Italy
    Antivir Ther 11:521-7. 2006
    ..This effect was particularly attributed to HCV-3, which was the only genotype associated with lower triglyceridaemia during HAART...
  20. ncbi Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 41:180-5. 2006
    ..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial...
  21. ncbi Impact of hepatitis C virus infection on lifestyle
    Paola Scognamiglio
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Via Portuense 292, Roma 00149, Italy
    World J Gastroenterol 13:2722-6. 2007
    ..To evaluate the impact of the diagnosis of hepatitis C infection on lifestyle habits such as smoking, drinking, sports activity and diet...
  22. ncbi Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
    ..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)...
  23. ncbi Antiretroviral drugs and liver injury
    Vincent Soriano
    AIDS 22:1-13. 2008
  24. ncbi Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Instituto di Ricerca e Cura a Carattere Scientifico, San Matteo Hospital, University of Pavia, Italy
    J Acquir Immune Defic Syndr 46:297-303. 2007
    ..This study was designed to investigate the incidence and type of liver-related complications and mortality in coinfected cirrhotic patients...
  25. ncbi Pathogenesis of liver damage in HCV-HIV patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    AIDS Rev 10:15-24. 2008
    ....
  26. ncbi Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a
    Paola Nasta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS 22:857-61. 2008
    ..To investigate the association between insulin resistance and rapid virologic response...
  27. ncbi Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
    ..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...
  28. ncbi Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 22:1399-410. 2008
    ..The present study represents an update of the current knowledge about HBV/HIV coinfection and an intent to provide practical advise about how to give the best care to HIV-infected persons with chronic hepatitis B...
  29. ncbi Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?
    Marco Bongiovanni
    Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    Clin Infect Dis 45:650-3. 2007
    ....
  30. ncbi Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  31. ncbi Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
    ....
  32. ncbi Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study
    Andrea Patroni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 3:451-61. 2002
    ..Lipid disturbances have also been associated with hepatitis C virus (HCV) chronic infection in HIV-uninfected participants. HAART-induced lipid abnormalities may then have peculiar features in HIV-HCV co-infected individuals...
  33. ncbi Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia--AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:419-20. 2002
  34. ncbi Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Arch Intern Med 162:2125-32. 2002
    ..The effect of chronic coinfection with hepatitis viruses on the response to therapy against human immunodeficiency virus 1 (HIV-1) remains debated...
  35. ncbi Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Disease IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    BMC Infect Dis 2:17. 2002
    ..In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule...
  36. ncbi Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali Università degli Studi di Brescia AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:324-32. 2002
    ..The search for the perfect treatment continues...
  37. ncbi Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue
    Raffaele Bruno
    J Acquir Immune Defic Syndr 30:535-6. 2002
  38. ncbi HCV chronic hepatitis in patients with HIV: clinical management issues
    Raffaele Bruno
    Division of Infectious and Tropical Disease, IRCCS S. Matteo Hospital, University of Pavia, Italy
    Am J Gastroenterol 97:1598-606. 2002
    ..Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease...
  39. ncbi Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC)
    Claudio Puoti
    Department of Gastroenterology and Internal Medicine, Genzano Hospital, Via Cimone 171, 00141 Rome, Italy
    J Hepatol 37:117-23. 2002
    ..To evaluate demographic characteristics, liver histology and virological features of hepatitis C virus (HCV) carriers with normal alanine transaminase (ALT) levels...
  40. ncbi Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects
    Massimo Puoti
    Clinica di Malattie Infecttive e Tropicali, Università degli studi de Brescia, AO Spedali Civili dei Brescia
    AIDS Rev 4:27-35. 2002
    ..Highly Active Anti-Hepatitis B Therapy will probably soon come of age...
  41. ncbi Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy
    Raffaele Bruno
    AIDS 17:783-4. 2003
  42. ncbi Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study
    Luz Martin-Carbonero
    Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 38:128-33. 2004
    ..The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority...
  43. ncbi Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 37:1678-85. 2003
    ..Preliminary results with some of them are quite promising and probably will widen the therapeutic armamentarium against hepatitis B in patients with HIV infection...
  44. ncbi Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
    Clin Infect Dis 40:e101-9. 2005
    ..We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype...
  45. ncbi Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 19:221-40. 2005
  46. ncbi Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome
    Massimo Puoti
    FClinica di Malattie Infettive, Università degli Studi di Brescia AO Spedali Civili, Brescia, Clinica di Malattie Infettive e Tropicali, Madrid, Spain
    AIDS 18:2285-93. 2004
    ..Hepatocellular carcinoma (HCC) is an increasing cause of mortality in HIV-seropositive individuals. The aim of the study was to compare the main features of HCC in HIV-seropositive individuals with those in to HIV-negative patients...
  47. ncbi The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
    Massimo Puoti
    Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy
    Antivir Ther 9:811-7. 2004
    ..3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen...
  48. ncbi Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Massimo Puoti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:627-30. 2004
    ..In summary, use of pegylated interferon appears to increase the risk of non-respiratory infections independently from neutropenia...
  49. ncbi A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili di Brescia, Universita di Brescia, Brescia, Italy
    J Hepatol 41:312-8. 2004
    ..To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients...
  50. ncbi Care of patients with hepatitis C and HIV co-infection
    Vincent Soriano
    AIDS 18:1-12. 2004
  51. ncbi Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  52. ncbi Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy
    Carlo Torti
    J Acquir Immune Defic Syndr 29:315-7. 2002
  53. ncbi CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy
    Stefan Mauss
    Hepatology 43:879; author reply 879-80. 2006
  54. ncbi Hepatitis B virus and HIV coinfection in low-income countries: unmet needs
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia, Italy
    Clin Infect Dis 46:367-9. 2008